Few have witnessed or perhaps even conceived of building an electric race car as a capstone or club activity. I’m not talking about Radio Shack remote-controlled battery-operated cars; I’m talking ...
As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back its early pipeline of autoimmune and cancer candidates. Originally launched ...
CAMBRIDGE, Mass., May 14, 2026 /PRNewswire/ -- CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune programming, today announced the closing of its $122 ...
NEW YORK – Create Medicines on Thursday said it raised $122 million in Series B financing to advance its pipeline of oncology and autoimmune in vivo CAR T-cell therapy candidates. The financing was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results